This Highlight offers a perspective on recent strategies for synthesising purine nucleoside antibiotics, an untapped source of natural products for developing novel antimicrobial agents.
Fluorinated glycans offer a prime opportunity to study the intricacies of their associated binding events with proteins, invoke resistance toward enzymatic hydrolysis, and modulate carbohydrate physicochemical properties. Sugar nucleotides are the key building blocks used by glycosyltransferases and associated enzymes to assemble glycans and, as such, represent a considerable landscape of opportunity to develop fluorinated motifs and enable structure-to-function understanding. Herein, we target the isosteric inclusion of fluorine within the nucleoside diphosphate sugar framework of GDP-mannose using a chemoenzymatic approach. Utilizing chemical synthesis to incorporate bespoke fluorine modifications and a promiscuous pyrophosphorylase, to assemble the sugar nucleotide, enables first-in-class access to GDP-mannoses containing fluorine within the nucleotide alongside double fluorination, within both the pyranose and nucleotide. These materials are utilized to probe a guanosine diphosphate mannose dehydrogenase critical to mucoid Pseudomonas aeruginosa alginate biosynthesis. This work provides an exemplar framework for incorporating fluorine within the nucleotide of derived sugar nucleotides and thus the capability to study glycosyltransferesase utilizing GDP-mannose more broadly.
The rapid emergence of RNA therapeutics has highlighted the need for more efficient, scalable and sustainable methods for their manufacture. Biocatalytic approaches hold particular promise, but rely on a secure, sustainable and low-cost supply of nucleoside triphosphate (NTP) building blocks, including those containing chemical modifications. Here we report the development of a biocatalytic approach and engineered enzymes to convert widely available nucleosides into NTPs featuring pharmaceutically relevant modifications using inexpensive phosphate donors. Importantly our strategy obviates the need for ATP as a phosphate donor that complicates NTP isolation using existing methods. To showcase the utility of our approach, we employ an engineered acid phosphatase, polyphosphate kinase and acetate kinase to produce 2′- O -methoxyethyl-ATP (2′-MOE-ATP) and 2′-fluoro-ATP, key building blocks of commercial therapeutics. Finally, we show that crude NTPs from our process can be used directly in enzymatic oligonucleotide synthesis, obviating the need for costly NTP isolation or purification steps.